2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Colorectal Neoplasms
25
Neoplasm Metastasis
15
Neoplasms
13
Rectal Neoplasms
8
Colorectal Cancer Metastatic
7
Colonic Neoplasms
6
Ovarian Neoplasms
5
Lymphoma, Non-Hodgkin
5
Uveal Melanoma
4
Sarcoma
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Melanoma
4
Lymphoma, Mantle-Cell
4
Lymphoma, Large-Cell, Immunoblastic
4
Lymphoma, Large B-Cell, Diffuse
4
Lymphoma, Follicular
4
Lymphoma, B-Cell, Marginal Zone
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Fallopian Tube Neoplasms
4
Carcinoma, Ovarian Epithelial
4
Burkitt Lymphoma
4
Uterine Cervical Neoplasms
3
Urinary Bladder Neoplasms
3
Urethral Neoplasms
3
Stomach Neoplasms
3
Prostatic Neoplasms
3
Lung Neoplasms
3
Glioblastoma
3
Endometrial Neoplasms
3
Carcinoma, Renal Cell
3
Interventions
salicylhydroxamic acid
1
brolucizumab
1
aflibercept
1
Triamcinolone Acetonide
1
Ranibizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Macular Degeneration
×
aflibercept
×
Clear all
NCT03710564
2023-01-30
MERLIN
Novartis
Phase 3
Terminated
535 enrolled
14 charts